SCHEMBL562336

SCHEMBL562336

COc1cc(O)cc(C=Cc2ccc(O)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 6/20 1.00
CYP1B1 Q16678 6/20 1.00
PTGS2 P35354 5/20 1.00
ALOX5 P09917 5/20 1.00
TTR P02766 4/20 1.00
KDM4E B2RXH2 5/20 0.89
NQO2 P16083 5/20 0.89
MEN1 O00255 4/20 0.89
MAPT P10636 4/20 0.89
KMT2A Q03164 4/20 0.89
ABL1 P00519 4/20 0.89
BCR P11274 4/20 0.89
PTGS1 P23219 3/20 0.89
ABCB1 P08183 3/20 0.89
NPC1 O15118 2/20 0.89
GAA P10253 2/20 0.89
RAB9A P51151 2/20 0.89
GFER P55789 2/20 0.89
HDAC6 Q9UBN7 2/20 0.89
MAPK1 P28482 1/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30475363 1.00 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5TTR
SCHEMBL562335 1.00 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5TTR
Pterostilbene SCHEMBL563218 0.94 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5TTR
Pterostilbene SCHEMBL28222684 0.94 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5TTR
Pterostilbene SCHEMBL3545782 0.94 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5TTR
Pterostilbene SCHEMBL20063 0.94 CYP1A1 (1.00) CYP1A1CYP1B1PTGS2ALOX5TTR
SCHEMBL2516449 0.92 PTGS2 (0.86) CYP1A1CYP1B1PTGS2ALOX5TTR
SCHEMBL2516446 0.92 PTGS2 (0.86) CYP1A1CYP1B1PTGS2ALOX5TTR
SCHEMBL29652111 0.92 PTGS2 (0.86) CYP1A1CYP1B1PTGS2ALOX5TTR
SCHEMBL29662231 0.92 PTGS2 (0.86) CYP1A1CYP1B1PTGS2ALOX5TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170087116-A1 Treatment of Inflammatory and Infectious Skin Disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-03-30 US claimed
US-20140018437-A1 TREATMENT OF INFLAMMATORY AND INFECTIOUS SKIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-01-16 US claimed
WO-2012129499-A1 TREATMENT OF INFLAMMATORY AND INFECTIOUS SKIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-09-27 WO claimed
US-20120178704-A1 PREVENTION AND TREATMENT OF COLON CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2012-07-12 US claimed
WO-2008070872-A1 PREVENTION AND TREATMENT OF COLON CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2008-06-12 WO claimed
EP-4743071-A2 DIPHENYLETHYLENE COMPOUNDS AND COMPOSITIONS THEREOF INNOVENE INC. (US) 2026-05-20 EP disclosed
WO-2025015023-A2 DIPHENYLETHYLENE COMPOUNDS AND COMPOSITIONS THEREOF INNOVENE, INC. (US) 2025-01-16 WO disclosed
WO-2024189607-A1 METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT DIDENKO KIRILL (MX) 2024-09-19 WO disclosed
CN-116637102-B Application of flavane compound in preparation of antitumor drugs 北京中医药大学 2024-04-09 CN disclosed
US-20230321002-A1 ANTICOCCIDIAL COMPOSITION COMPRISING STILBENE-BASED COMPOUND, AND USE THEREOF CJ CHEILJEDANG CORPORATION (KR) 2023-10-12 US disclosed
CN-116637102-A Application of flavane compound in preparation of antitumor drugs 北京中医药大学 2023-08-25 CN disclosed
EP-4218419-A1 ANTICOCCIDIAL COMPOSITION COMPRISING STILBENE-BASED COMPOUND, AND USE THEREOF CJ Cheiljedang Corporation (KR) 2023-08-02 EP disclosed
US-20090047309-A1 COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN ELC MANAGEMENT LLC 2009-02-19 US disclosed
US-20090035243-A1 Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035240-A1 Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035242-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035236-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent ELC MANAGEMENT LLC 2009-02-05 US disclosed
US-20090035237-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant ELC MANAGEMENT LLC 2009-02-05 US disclosed
WO-2008070872-A1 PREVENTION AND TREATMENT OF COLON CANCER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2008-06-12 WO disclosed
US-20050038125-A1 Method for the treatment of arthritis and pain N.V. NUTRICIA (NL) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035243-A1 Anhydrous Cosmetic Compositions Containing Resveratrol Derivatives RB1, SIRT1, EP300 CYP1A1 1440/4885CYP1B1 902/4885PTGS2 3838/4885
US-20090035242-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Linear Or Branched Silicone SQLE, SMURF1, PIK3R1 CYP1A1 2625/4885CYP1B1 1478/4885PTGS2 3228/4885
US-20090047309-A1 COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN CUTA, ERCC1, OGG1 CYP1A1 253/4885CYP1B1 269/4885PTGS2 3235/4885
US-20120178704-A1 PREVENTION AND TREATMENT OF COLON CANCER APC, SI, NFKBIA CYP1A1 1123/4885CYP1B1 1133/4885PTGS2 28/4885
US-20090035237-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And Silicone Surfactant SMURF1, CUTA, SMURF2 CYP1A1 2419/4885CYP1B1 2175/4885PTGS2 3901/4885
US-20090035236-A1 Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent CUTA, LRAT, RARA CYP1A1 1737/4885CYP1B1 1935/4885PTGS2 2396/4885
US-20090035240-A1 Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent SMARCC1, RARG, RARA CYP1A1 1950/4885CYP1B1 1679/4885PTGS2 3031/4885
US-20230321002-A1 ANTICOCCIDIAL COMPOSITION COMPRISING STILBENE-BASED COMPOUND, AND USE THEREOF VIP, NFATC1, CASP3 CYP1A1 4700/4885CYP1B1 4437/4885PTGS2 2020/4885
US-20050038125-A1 Method for the treatment of arthritis and pain LTB4R2, LTB4R, LTC4S CYP1A1 400/4885CYP1B1 235/4885PTGS2 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.